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Osteoarthritis (OA) is the most common form of arthritis and a leading cause of disability worldwide,
largely due to pain, the primary symptom of the disease. The pain experience in knee OA in particular is
well-recognized as typically transitioning from intermittent weight-bearing pain to a more persistent,
chronic pain. Methods to validly assess pain in OA studies have been developed to address the complex
nature of the pain experience. The etiology of pain in OA is recognized to be multifactorial, with both
intra-articular and extra-articular risk factors. Nonetheless, greater insights are needed into pain
mechanisms in OA to enable rational mechanism-based management of pain. Consequences of pain
related to OA contribute to a substantial socioeconomic burden.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The hallmark symptom of osteoarthritis (OA), themost common
form of arthritis, is pain. This is the symptom that drives individuals
to seek medical attention, and contributes to functional limitations
and reduced quality of life1e4. Largely because of pain, lower ex-
tremity OA is well-recognized as the leading cause of mobility
impairment in older adults in the US5,6.The scope of the problem
Approximately 27 million US adults and 8.5 million UK adults
are estimated to have clinical OA deﬁned on the basis of symptoms
and physical ﬁndings7,8. Prevalence of OA increases with age; 13.9%
of adults age 25 and older have clinical OA of at least one joint,
while 33.6% of adults age 65 and older have OA9.
In large epidemiologic studies, OA is often deﬁned on the basis
of standard radiographic assessments, such as the Kellgren and
Lawrence grade. Symptomatic OA indicates the presence of both
radiographic OA and symptoms (i.e., pain, aching, stiffness) in the
same joint attributable to OA; as such, its prevalence is generally
lower than that of radiographic OA (i.e., regardless of symptoms).
For example, the prevalence of radiographic knee OA was 19% and
28% among adults age 45 years in the Framingham study and
Johnston County Osteoarthritis Project, respectively, while theT. Neogi, 650 Albany Street,
ing Unit, Boston, MA 02118,
s Research Society International. Pprevalence of symptomatic knee OAwas 7% in Framingham and 17%
in the Johnston County Osteoarthritis Project10,11. The prevalence of
symptomatic knee OA in two UK studies ranged from 11 to 19%, and
estimates of 5e15% were noted in surveys undertaken in other
countries12.
Symptomatic hip OA has been reported to be 9% in the Johnston
County Osteoarthritis Project, with lower prevalence estimates of
0.7e4.4% in the UK13,14. The prevalence of symptomatic hand OA is
higher, with the age-standardized prevalence of symptomatic hand
OA being 14.4% and 6.9% in women and men, respectively, in
younger Framingham cohorts15, increasing to 26.2% and 13.4%,
respectively, among those age 71 in an older Framingham
cohort16. Another study reported an estimate of 8% among adults
age 60 and older17. Incidence of symptomatic hand OAwas reported
to be 9.7% for women and 4% for men over a 9-year period15.
The lifetime risk of developing symptomatic knee OA is esti-
mated to be w45% (40% in men and 47% in women) based upon
Johnston County Osteoarthritis Project data, with risks increasing
to 60.5% among persons who are obese, which is approximately
double the risk of those who are of normal weight or are un-
derweight18. With aging of the population and increasing obesity,
the prevalence of OA is expected to rise. Indeed, an increase in
prevalence of symptomatic knee OA over the past 20 years has
been noted in the Framingham cohort, rising by 4.1% and 6%
among women and men, respectively, intriguingly without a
concomitant parallel rise in prevalence of radiographic OA19.
Based upon National Health Interview Survey (NHIS) data, the
estimated number of US adults with doctor-diagnosed arthritis,
the majority of which is related to OA and likely symptomatic if it
has had medical attention, is projected to increase to nearly 67
million by 203020.ublished by Elsevier Ltd. All rights reserved.
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related to OA during their lifetime. Further, individuals with OA in
one joint will often have OA in another joint(s), with resulting
greater symptomatic burden of the disease.
The pain experience in OA
The International Association for the Study of Pain deﬁnes pain
as “an unpleasant sensory and emotional experience associated
with actual or potential tissue damage, or described in terms of
such damage.”21 It is a complex subjective phenomenon, with each
individual having a unique perception of it, inﬂuenced by biolog-
ical, psychological and social factors22. Under normal circum-
stances, pain is a warning that something is wrong: pain from
touching a hot stove, having injured a joint, or chest pain due to
ischemia, for example. In these instances, pain plays a protective
role, signaling to the individual to withdraw from the threat, rest to
allow tissue healing, or seek help, etc. However, once its warning
role is over, persistence or continued pain, i.e., chronic pain, is
considered maladaptive.
Unlike many other pain conditions in which the underlying
injury typically heals or resolves, OA is a disease that does not
resolve. Thus, OA is typically accompanied by chronic pain.
Whether, and to what degree, this ongoing chronic pain (i) plays an
important nociceptive role, (ii) represents maladaptive pain, or (iii)
reﬂects other aspects of the pain experience is not clear.
The pain experience among persons with OA has been evaluated
through a number of qualitative research efforts. In the ﬁrst qual-
itative study to focus explicitly on pain and related distress as well
as changes in pain over time by Hawker et al., individuals with hip
and knee OA identiﬁed two distinct types of OA pain: one that was
intermittent but generally severe or intense, and another that was a
persistent background pain or aching23. Stages of OA-related pain
could be discerned, with early stages characterized by activity-
related pain, becoming more constant over time and punctuated
by intermittent intense pain. A decrease in participation subse-
quently occurs in an attempt to avoid triggering such episodes. The
more intense but less frequent pain that comes and goes (i.e.,
intermittent), particularly when unpredictable, had greater impact
on quality of life than the ‘background’ (i.e., constant) pain. The pain
had negative effects on mood, participation in social and recrea-
tional activities, and sleep. Similar ﬁndings were noted in another
study of individuals who had a recent diagnosis of knee OA or were
symptomatic but undiagnosed (i.e., “prediagnostic knee OA”)24. The
signiﬁcance of intermittent knee symptoms was not clear for
several years before participants became aware of development of
chronic knee symptoms. They then altered activities to avoid more
symptoms, until symptoms affected participation, at which time
they sought medical care.
In addition to the concepts of “intermittent” and “constant”
pain, the intensity of daily pain varies widely25, although the un-
derlying reasons for such variation are not well-understood. The
quality of pain in OA also varies, with approximately one-third of
individuals with knee OA using descriptors such as burning,
tingling, numbness, and pins and needles to characterize their knee
symptoms26. Such descriptors suggest that neuropathic pain may
contribute to the OA pain experience, although speciﬁc nerve le-
sions have not been identiﬁed in OA.
Pain assessment in OA
Given the variation in pain intensity, frequency, pattern, and
quality in OA, a single, simple question about pain is unlikely to
adequately capture the full pain experience. Some of the variation in
reported prevalence of symptomatic OA is related to differences instudydesignandpopulationsexamined, but importantly, it is alsodue
to the way in which questions about knee pain were formulated.
Differences in descriptors used to assess pain (e.g., “pain” vs “pain,
aching, or stiffness”) may elicit different responses. Duration over
which pain is being assessed (e.g., “pain on most days of a month in
the past year” vs “pain onmost days of the pastmonth”) can be prone
to recall bias. Ideally, uniform, standardized, and valid questionnaires
should be used to evaluate pain, particularly to enable more precise
pain phenotyping and facilitate cross-study comparisons, genetic
association studies, and drug trial protocol development.
In OA cohort studies and trials, a number of approaches are
typically used to assess pain. For evaluation of kneeOA pain, themost
common are a visual analog scale (VAS) or numerical rating scale
(NRS) assessment of pain intensity; a single question about presence
of “pain, aching of stiffness in or around the knee” over a speciﬁed
period of time; and/or the pain subscale of the Western Ontario and
McMaster Universities Arthritis Index (WOMAC)27 or the Knee injury
and Osteoarthritis Outcome Score (KOOS)28. The pain subscales of
these latter two instruments assess pain experienced with speciﬁc
activities. As a result, the pain and function subscale scores are highly
correlated. Nonetheless, these validated instruments are responsive
and are used in assessing efﬁcacy of interventions. A number of
additional validated generic pain instruments are available that are
also appropriate for use in OA29. A meta-analysis concluded that
different patient-reported outcome measures of pain severity have
generally comparable responsiveness to treatment, with the single-
item pain assessments with the VAS or NRS resulting in effect esti-
mates comparable to the WOMAC pain subscale, although their
mean standardized effect sizes were lower30. To enable meaningful
interpretation of response to therapy rather than relying on
mean group responses, the Outcome Measures in Rheumatology-
Osteoarthritis Research Society International (OMERACT-OARSI) set
of responder criteria were developed and validated for use in clinical
trials31. To be considered a responder, at least a minimum threshold
of relative and absolute improvement in pain or a lesser degree of
absolute and relative improvement in at least two out of three do-
mains (pain, function, patient global assessment) is required.Many of
these samequestions and instruments (e.g.,WOMAC) can be used for
hip OA; the Hip disability and Osteoarthritis Outcome Score (HOOS)
is speciﬁc for hip OA32. To assess pain, stiffness and physical func-
tioning in hand OA, the Australian/Canadian Osteoarthritis Hand
Index (AUSCAN) is commonly used33.
Despite widespread use of these pain assessments, the complex
pain experience of those living with OA is not adequately captured
by existing measures. To address this issue, a multicenter interna-
tional Osteoarthritis Research Society International/Outcome
Measures in Rheumatology (OARSI/OMERACT) initiative led to
development of a new measure informed by qualitative research
ﬁndings that was subsequently validated. This new instrument,
Intermittent and Constant OA Pain (ICOAP), assesses various facets
regarding both intermittent and constant pain for the knee and hip
separately, including frequency (for intermittent pain), intensity,
effects on sleep and quality of life, degree of frustration or annoy-
ance and upset or worried feelings associated with the pain, as well
as whether the intermittent pain occurs without warning or after a
trigger34. The ICOAP has recently been demonstrated to be
responsive to change in intervention studies35.
In keeping with the acknowledgment of the multidimensional
nature of pain, the Initiative on Methods, Measurement, and Pain
Assessment in Clinical Trials (IMMPACT) has recommended six core
domains and associated measures that should be considered when
studying any type of chronic pain in clinical trials: pain (intensity
and use of rescue medications), physical functioning (with a focus
on pain interference), emotional functioning, participant ratings of
improvement and satisfaction with treatment, symptoms and
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related to pain in OA include fatigue, sleep, and cognition. With the
increasing importance of patient-reported outcomes, the NIH-
funded Patient Reported Outcomes Measurement Information
System (PROMIS) provides an opportunity to collect a variety of
validated patient-reported health outcomes related to physical,
mental, and social well-being, in addition to pain.
Risk factors for pain in OA
In view of the complex, multidimensional nature of the pain
experience in OA, it is perhaps not surprising that the underlying
etiology of pain is multifactorial, most often considered in a bio-
psychosocial framework (Fig. 1). A few such risk factors are dis-
cussed below.
The extent to which structural pathology in OA contributes to
the pain experience has been controversial. A structure-symptom
discordance in OA has been widely noted, based upon observa-
tions of weak correlations between radiographic severity of OA and
pain presence or severity, although the discordance is less with
more severe stages of radiographic disease10,38e43. In a systematic
review, 15e76% of those with knee pain had radiographic OA, and
15e81% of those with radiographic OA had knee pain44. The extent
of additional X-ray views obtained, the deﬁnition of pain symp-
toms, and the nature of the study sample (e.g., age, race) affected
the prevalence of these ﬁndings, and therefore interpretation of the
degree of concordance. For example, in studies evaluating both the
tibiofemoral and patellofemoral joints that also obtained WOMAC
pain assessments, a more consistent association was noted be-
tween pain severity and radiographic OA45,46. Supporting such
ﬁndings, a randomized trial demonstrated intra-articular lidocaine
to effectively decrease knee pain in comparison with placebo47,
lending further support to the notion that structural pathology
within the knee must be contributing to pain.
Beyond measurement issues, there are additional reasons that
contribute to an apparent discordance. As discussed above, pain is a
subjective experience, inﬂuenced by a number of factors, including
genetic predisposition48,49, prior experience50,51, expectations
about analgesic treatment52,53, current mood54, coping strategies
and catastrophizing55, and sociocultural environment56e58, as
some examples. Without taking into account such factors that can
contribute to between-person differences, assessment of the rela-
tion of structure to symptoms will be confounded. Unfortunately
most such factors that contribute to individual variation in painPsychological 
Factors Genetics Joint Pathology
Sociocultural 
Factors 
OA-related Pain
Function
Participation/
Disability
Health-related 
Quality of life
Fig. 1. Schematic illustrating the multifactorial nature of pain in OA, with complex inter-re
pain.cannot be feasibly measured or collected in most studies. By
adequately controlling for between-person differences using a
within-person knee-matched approach, a strong doseeresponse
relationship can be demonstrated between radiographic severity
and pain presence, severity, and incidence (i.e., new onset)59,60.
While such studies provide conﬁrmation that structural pa-
thology of OA does indeed contribute to the pain experience, ra-
diographs do not provide insight into what particular structural
pathologies may contribute to such pain. A review elsewhere in this
issue examines the structural correlates of pain in greater detail
(REF). In brief, based upon MRI studies, bone marrow lesions, sy-
novitis, and effusions appear to have the greatest evidence sup-
porting their relation to pain in OA to date61.
Although such studies have highlighted the importance of
structural pathology to pain in OA, attempts at structure modiﬁ-
cation have been largely unsuccessful to date with regards to pain.
Some recent exceptions include promising pain results from trials
evaluating zoledronic acid targeting bone marrow lesions, with
possible additional bone and cartilage effects, and strontium
ranelate which may have both bone and cartilage effects62,63.
Other risk factors for pain in OA may be more amenable to
modiﬁcation. Psychological factors are well-recognized as being
correlated with pain in OA, and the role of cognitive behavioral
therapy is outlined elsewhere in this issue39,64 (þREF). Specif-
ically, some traits, such as catastrophizing, coping, and self-
efﬁcacy may be amenable to intervention65e67. While depres-
sion, anxiety, and negative affect, among others, have been
associated with OA pain42,68, the causal direction of such re-
lationships is difﬁcult to discern. Fluctuation in pain has been
linked to ﬂuctuation in psychological factors, but whether the
pain inﬂuences the mood or vice versa is difﬁcult to disentangle69.
Although psychological factors can certainly contribute to a
heightened pain experience, it is also possible that pain itself can
contribute to poor mood. Such relationships can only be dis-
cerned from longitudinal studies, of which there are relatively
few to date. For example, pain from OA contributed to functional
limitations and fatigue, which in turn contributed to depressed
mood and worse pain and function in one study evaluating these
complex inter-relationships70. Functional brain imaging studies of
OA also demonstrate an important role of affective and motiva-
tional aspects of pain71,72 that should be addressed to improve
effective management of OA-related pain. This is particularly
important in light of the prevalence and impact of comorbid
mood disorders on health outcomes.Neurobiological 
Mechanisms Other Factors
Socioeconomic Burden of OA
lationships between various risk factors, and the potential wide-ranging effects of OA
T. Neogi / Osteoarthritis and Cartilage 21 (2013) 1145e11531148Weight is a potential modiﬁable factor contributing not only to
OA risk, but also to pain. The effect of obesity on pain may be two-
fold. For the lower extremities, the effect of excess weights on
symptoms may be due to mechanical loading. Increased relative fat
mass in obesity may potentially contribute to pain symptoms
related to elaboration of adipokines, although studies are conﬂict-
ing in this regard73,74. While the mechanism by which obesity
contributes to pain may not be clear, effects of altering weight on
OA-related pain have been studied. Observational cohort data was
used to demonstrate a lower risk of developing symptomatic knee
OA among womenwho lost 5 kg75. Subsequent randomized trials
have noted reductions in pain with w10% weight loss76e78, with
more substantial effects on pain reduction with greater weight
loss79. Importantly, weight gain signiﬁcantly increases pain, high-
lighting the doseeresponse relationship of change in weight with
change in pain80.
While not directly modiﬁable, there may be a genetic predis-
position to development of chronic pain or experiencing greater
pain severity that may provide insight into novel therapeutic tar-
gets. The availability of large cohort studies with standardized pain
and X-ray data has facilitated genetic association studies to address
such hypotheses. A functional polymorphism (Val158Met) in the
COMT gene, which has been associated with pain sensitivity in
other clinical conditions, was associated with hip OA-related pain
in one cohort study81, but has not yet been replicated in other co-
horts. TRPV1 and the PACE4 gene PCSK6 were associated with pain
in knee OA in two separate meta-analyses82,83, while an association
with a SCN9 SNP could not be replicated84. A missense variant in
P2RX7, a target identiﬁed through a genome-wide screen in mice
with assessment of mechanical allodynia, has been associated with
OA-related pain in one cohort85. Greater details of genetic de-
terminants of pain can be found elsewhere in this issue (REF).
Another area that may provide potential therapeutic targets is
related to risk factors that contribute to the transition from acute to
chronic pain in OA, which at present is not well-understood. As
noted in the qualitative work described above, there is a general
progression of symptoms from the early stages of OA with activity-
related (e.g., weight-bearing) symptoms that appear to be noci-
ceptive in nature, to a more persistent constant pain that likely
reﬂects other additional processes, such as neurobiological mech-
anisms. Tissue injury and/or inﬂammation, as may be seen in OA,
leads to a decrease in the excitation threshold and an increase in
responsiveness to suprathreshold stimuli of peripheral nociceptors,
i.e., peripheral sensitization86e88. Noxious mechanical stimuli can
then evoke exaggerated responses (primary hyperalgesia), and
normally innocuous stimuli, such as movement of the joint through
its normal range of motion, may evoke a pain response (allodynia).
As a result of nociceptor activity after tissue injury or inﬂammation,
a number of changes occur in the central nervous system. These
include changes to dorsal horn transmission neuron receptors,
leading the transmission neurons to become increasingly respon-
sive to peripheral input (central sensitization), with reduction in
the threshold for mechanically induced pain and an expansion of
the receptive ﬁeld of dorsal horn neurons (spatial summation)89.
Radiating pain in OA likely reﬂects this latter phenomenon. Once
established, central sensitization is maintained by low-level
noxious and even non-nociceptive input from the periphery90.
Such changes in the central nervous system are mainly responsible
for the enhanced sensitivity to mechanical stimuli that develops
outside the area of the injury (secondary hyperalgesia)91e93.
Beyond the clinical observations of hyperalgesia, allodynia, and
radiating pain that suggest a role for sensitization in OA-related
pain, there are some experimental neurophysiologic ﬁndings that
also support the presence of sensitization in OA. Persons with knee
OA experience a greater intensity, duration, and area ofhyperalgesia after intramuscular injection of hypertonic saline
comparedwith controls94. Lidocaine injected into a painful OA knee
resulted in pain reduction in both the injected knee and the un-
treated contralateral knee, supporting central pain modulation in
OA47. Persons with knee OA have higher pain intensities compared
with controls to the same level of pressure stimuli, as well as lower
pressure pain thresholds95. Other studies have also documented
lower pain thresholds in persons with OA compared with con-
trols96e98. Temporal summation, a progressive increase in dis-
charges of dorsal horn neurons in response to repetitive afferent
stimulation thought to reﬂect central sensitization, is increased in
persons with painful knee OA compared with age-matched healthy
controls, and the degree of sensitization correlated with pain99.
What pathologies of OAmay contribute to peripheral and/or central
sensitization, other risk factors for sensitization, and identiﬁcation
of the transition from appropriate nociceptive input to sensitization
are important research questions that need to be addressed for
improved understanding of pain mechanisms in OA. In addition,
further development and validation of tools to assess sensitization
will be necessary to support such research efforts100.
Thus, there appears to be substantial opportunities to gain
further insights into causes and contributors to pain in OA. Such
insights in turn will provide opportunities for rational mechanism-
based targeting of pain for more efﬁcacious therapeutic manage-
ment of OA patients.
Impact of OA-related pain
Because effective treatment for OA and its related pain is not
available to date, and the disease can be present for decades, the
public health impact of OA is substantial on an individual and so-
cietal level (Fig. 1). With the high prevalence of knee OA globally101,
not only is OA a leading cause of disability among older adults in the
US5,6, but it is among the top 10 causes of disability world-
wide101,102. In recent estimates of global years lived in disability,
musculoskeletal-related conditions ranked second, with low back
pain, neck pain, and knee OA being the three most common such
conditions, and knee OA itself ranked within the top 10 non-
communicable diseases for global disability-adjusted life years (i.e.,
years of life lost and years lived with disability)102.
Symptoms such as pain, stiffness, and gelling in OA have clear
contributions to functional limitations in OA, with well-
documented associations of pain severity with degree of func-
tional limitation103,104. While most of the research focus to date has
been on the knee or hip, symptomatic hand OA has important
functional limitations, predominantly related to weaker grip
strength and activities requiring precise pincer grip or power
grip16. Nonetheless, a particular focus on lower extremity OA is
warranted given the high prevalence of associated disability. In a
longitudinal panel survey conducted by the US Census bureau,
arthritis or rheumatism was the most commonly reported cause of
disability, and difﬁculties related to lower extremity functioning or
activities were the most commonly reported limitations among all
respondents105. Speciﬁcally, the most common limitation was in
walking three city blocks, which affected an estimated 22.5 million
US adults, and difﬁculty with climbing stairs, affecting an estimated
21.7 million US adults105. While not all such individuals have
symptomatic knee or hip OA, it is likely that OA accounts for a large
proportion of these limitations. Based upon NHANES III data,
among persons with OA, about 80% have some degree of movement
limitation and 25% cannot perform major activities of daily living;
11% of adults with knee OA require help with personal care, and 14%
require help with routine needs9. Symptomatic knee OA can have
less obviously apparent effects on functioning as well. For example,
persons with knee OA have slower walking speeds than those
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faster decline in gait speed over time than those with either knee
OA alone or knee pain alone107. It is not surprising that knee pain
also leads to restrictions in mobility outside of the house, impacting
upon participation108.
Symptomatic OA’s economic impact is also substantial. Average
direct medical charges related to OA care were estimated to be
w$2,600 per year per individual in 1997109, and the total (i.e., direct
and indirect) annual disease costs were estimated to be $5,700 per
individual (USD, FY 2000)110. Those costs need to be considered in
the context of the prevalence of the disease to appreciate the
overall societal economic impact. OA as a primary diagnosis
accounted for 11.25 million (22.3%) of all arthritis-related ambula-
tory medical care visits in 2006111. Further, arthritis-related con-
ditions were the second most common reason for medical visits
related to chronic conditions in 2005, second only to hypertension,
which is asymptomatic112. In terms of inpatient costs, OA was the
ﬁfth most expensive condition treated in US hospitals in 2008, with
a cost of w$40 billion in total national hospital expenditures,
comprising 3.5% of the national hospital bill, and accounting for 70%
of all arthritis-related inpatient hospitalizations111,113. Much of
those hospitalizations were related to joint replacement surgery.
Pain is clearly among the main reasons for individuals seeking joint
replacement. Knee replacement surgeries are one of the most
commonly performed orthopedic procedures in the US, withw50%
of all joint arthoplasties performed on the knee, and 97% of those
are performed for knee OA111. In 2004, 478,000 knee replacement
surgeries were performed, representing a three-fold increase since
1991, with total hospitalization charges of $14.26 billion in
2004111,114,115. This increase exceeds expectations based upon
overall population growth and increase in the proportion of the
population that is elderly and/or obese. The demand for primary
total knee replacement is expected to grow by 673% to 3.48 million
procedures by 2030116. Adding to these costs is the increase in
health care utilization in the 2 years preceding the surgery117.
To appreciate the total economic burden of OA on society, in-
direct or productivity costs must also be examined. Productivity
costs typically reﬂect costs due to lost productivity while being
present at work, costs due to absence from work, and costs for
compensation of household work by others118. Unfortunately, there
are signiﬁcant variations among indirect cost studies in OA
regarding methodology, cost estimation, and cost presentation,
limiting one’s ability to determine the magnitude of OA’s economic
impact119. For example, in one review, indirect costs of OA per
patient per year varied from $831 in Hong Kong to $12,789 in
Canada (costs in 2006 USD)119. Considering the prevalence of OA,
work-related OA costs have been estimated to range from $3.4 to
$13.2 billion per year120. Estimates from 1999 indicate that adults
with knee OA reportedmore than 13 days of lost work due to health
issues9. Using a more recent large US employer beneﬁts database,
those with OA had an average of 63 days of absenteeism compared
with 37 days among a matched comparator group, with mean total
direct and indirect costs being two- to three-fold higher121. Similar
ﬁndings were noted in a Swedish population-based cohort, in
which those with physician-diagnosed knee OA had a two-fold
increased risk of sick leave and 40e50% increased risk of disability
pension compared with the general population122. Further,w2% of
all sick days in the population were attributable to knee OA. In a
systematic literature review regarding work participation, occu-
pational limitations and reduced work capacity or job effectiveness
were reported more frequently in those with OA than by con-
trols123. Aggregate annual absenteeism costs of OA were estimated
to bew$10 billion from the US Medical Expenditure Panel Survey,
higher than many other major chronic diseases124. Taking into ac-
count both productivity costs and medical costs among adults withpaid employment in a study from the Netherlands, the total eco-
nomic burden of knee OAwas estimated to beV871 per person, per
month, with the majority of the costs being related to productiv-
ity118. Regardless of the methodologic differences, issues with cost
estimation, and difﬁculties in comparing costs across studies, it is
clear that OA has a tremendous economic impact that will only
continue to grow with its rising prevalence.
Summary
OA is highly prevalent worldwide, with a tremendous symp-
tomatic and economic global burden. Although a number of risk
factors have been identiﬁed for pain in OA, the research focus to
date has primarily been on structural targets. Pharmacologic
treatment options remain limited and nonpharmacologic options
are underutilized. An expansion of the research agenda to more
fully explore painmechanisms operational in OA is urgently needed
to enable comprehensive mechanism-based pain management
strategies in this prevalent, disabling, and costly disease.
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